These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26136882)

  • 1. Intra-tumor heterogeneity of
    Tatematsu T; Sasaki H; Shimizu S; Hikosaka YU; Okuda K; Haneda H; Moriyama S; Yano M; Fujii Y
    Exp Ther Med; 2015 May; 9(5):1719-1722. PubMed ID: 26136882
    [No Abstract]   [Full Text] [Related]  

  • 2. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
    Yancovitz M; Litterman A; Yoon J; Ng E; Shapiro RL; Berman RS; Pavlick AC; Darvishian F; Christos P; Mazumdar M; Osman I; Polsky D
    PLoS One; 2012; 7(1):e29336. PubMed ID: 22235286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
    Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
    Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
    Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
    Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
    de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib.
    Garbe C; Eigentler TK
    Recent Results Cancer Res; 2018; 211():77-89. PubMed ID: 30069761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
    Sasaki H; Shimizu S; Tani Y; Shitara M; Okuda K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Lung Cancer; 2013 Oct; 82(1):51-4. PubMed ID: 23927882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
    Yousem SA; Nikiforova M; Nikiforov Y
    Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report.
    Peker YS; Can MF; Ozerhan IH; Yagci G; Zeybek N; Kavakli K; Gurkok S; Gozubuyuk A; Genc O; Erdem G; Ozet A; Gerek M; Peker Y
    Case Rep Surg; 2018; 2018():8782328. PubMed ID: 29850361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
    Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
    J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.
    Yang Y; Meng Y; Zhang H; Shen X; Li R; Yu L; Liu B; Wang L
    Oncol Lett; 2018 Mar; 15(3):3295-3304. PubMed ID: 29467863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
    Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
    Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.